Laboratorio Elea Phoenix S.A.
Quick facts
Marketed products
Phase 3 pipeline
- Bevacizumab (Lumiere®) · Oncology
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. - Pembrolizumab biosimilar · Oncology
This biosimilar blocks PD-1 on immune cells to restore anti-tumor immunity by preventing tumor cells from suppressing T-cell responses. - Short regimen of benznidazole · Infectious Disease / Parasitology
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites. - Short treatment with benznidazole · Infectious Disease / Parasitology
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease. - Standard treatment with benznidazole · Infectious Diseases
Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: